Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical
presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; …

Abstract Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic
treatment of Parkinson's disease (PD). MAO-B inhibitor monotherapy has been shown to be …

Background and Objectives There is growing interest in health-related quality of life
(HRQOL) as a comprehensive view of the patient's well-being, guiding concept for the …

In patients affected by Parkinson's disease (PD), up to 50% of them experience cognitive
changes, and psychiatric disturbances, such as anxiety and depression, often precede the …

Quality of life (QOL) plays an important role in independent living in Parkinson's disease
(PD) patients, being crucial to know what factors impact QoL throughout the course of the …

Background and objective Patients with young-onset Parkinson's disease (YOPD) have a
slower progression. Our aim was to analyze the change in cognitive function in YOPD …

Parkinson's disease (PD) is a chronic and complex neurodegenerative disorder.
Conventional pharmacological or surgical therapies alone are often insufficient at …

Some studies observed a benefit of Parkinson's disease (PD) patients after treatment with
safinamide in some non-motor symptoms (NMSs). The aim of this study was to analyze the …

Background Prevalence rates of sexual dysfunction (SD) in Parkinson's disease (PD) are
likely to be underestimated and their etiology is still unknown. More understanding of this …

Parkinson's disease (PD), the second most prevalent neurodegenerative disorder, manifests
with motor and non-motor symptoms associated with two main pathological hallmarks …